PDCD1 and hepatocellular carcinoma: Finally, a randomized, open-label, multicenter study (ORIENT-32 trial, NCT03794440) is testing the combination of IBI305 (anti-VEGF monoclonal antibody) with sintilimab (anti-PD-1 monoclonal antibody) in participants with advanced HCC as the first-line treatment compared with sorafenib (Table 3).